Incepta launches new drug for fatty liver and MASH

Liver diseases, particularly fatty liver and metabolic dysfunction associated steatohepatitis (MASH), are emerging as leading health challenges in Bangladesh.
Incepta Pharmaceuticals has introduced a new medicine, Frehepta (generic name: Resmetirom), for the treatment of fatty liver and MASH. This is the first time the drug has been made available in Bangladesh, says a press statement.
Globally, Resmetirom has shown promising results in managing fatty liver and MASH, including a significant reduction in liver fat, improvement in fibrosis markers, and a lower risk of adverse effects.
Incepta Pharmaceuticals has introduced Frehepta at an affordable price, emphasising that it should only be used under the prescription of a registered physician.